# Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

> **NCT02273765** · PHASE3 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 460 (actual)

## Conditions studied

- HIV-1 Infection
- Tuberculosis

## Interventions

- **DRUG:** Tenofovir + lamivudine + raltegravir
- **DRUG:** Tenofovir + lamivudine + efavirenz

## Key facts

- **NCT ID:** NCT02273765
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-11
- **Primary completion:** 2018-11-28
- **Final completion:** 2018-11-28
- **Target enrollment:** 460 (ACTUAL)
- **Last updated:** 2018-12-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273765, "Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02273765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*